These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35281784)

  • 21. SARS-CoV-2 Omicron variant infection affects blood platelets, a comparative analysis with Delta variant.
    Garcia C; Compagnon B; Ribes A; Voisin S; Vardon-Bounes F; Payrastre B
    Front Immunol; 2023; 14():1231576. PubMed ID: 37828997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq.
    Rashid PMA; Salih GF
    Mol Biol Rep; 2022 Aug; 49(8):7437-7445. PubMed ID: 35698014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Period Study Results from a Large Italian Hospital Laboratory Attesting SARS-CoV-2 Variant PCR Assay Evolution.
    Liotti FM; De Maio F; Ippoliti C; Santarelli G; Monzo FR; Sali M; Santangelo R; Ceccherini-Silberstein F; Sanguinetti M; Posteraro B
    Microbiol Spectr; 2022 Dec; 10(6):e0292222. PubMed ID: 36409091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.
    Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues.
    Kim S; Nguyen TT; Taitt AS; Jhun H; Park HY; Kim SH; Kim YG; Song EY; Lee Y; Yum H; Shin KC; Choi YK; Song CS; Yeom SC; Kim B; Netea M; Kim S
    Immune Netw; 2021 Dec; 21(6):e38. PubMed ID: 35036025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
    Dhawan M; Saied AA; Mitra S; Alhumaydhi FA; Emran TB; Wilairatana P
    Biomed Pharmacother; 2022 Oct; 154():113522. PubMed ID: 36030585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoinformatics and MD-simulation data suggest that Omicron spike epitopes are more interacting to IgG via better MHC recognition than Delta variant.
    Sarkar A; Santra D; Sundar Panja A; Maiti S
    Int Immunopharmacol; 2023 Oct; 123():110636. PubMed ID: 37499394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omicron variant evolution on vaccines and monoclonal antibodies.
    Sabbatucci M; Vitiello A; Clemente S; Zovi A; Boccellino M; Ferrara F; Cimmino C; Langella R; Ponzo A; Stefanelli P; Rezza G
    Inflammopharmacology; 2023 Aug; 31(4):1779-1788. PubMed ID: 37204696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of SARS-CoV-2 in Saliva and Nasopharyngeal Swabs According to Viral Variants.
    Salmona M; Chaix ML; Feghoul L; Mahjoub N; Maylin S; Schnepf N; Jacquier H; Walle EM; Helary M; Mellon G; Osinski N; Zebiche W; Achili Y; Amarsy R; Mahé V; Le Goff J; Delaugerre C
    Microbiol Spectr; 2022 Dec; 10(6):e0213322. PubMed ID: 36346252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant.
    Samanta A; Alam SSM; Ali S; Hoque M
    EXCLI J; 2022; 21():610-620. PubMed ID: 35651657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022.
    Wolf JM; Wolf LM; Bello GL; Maccari JG; Nasi LA
    J Med Virol; 2023 Jan; 95(1):e28366. PubMed ID: 36458547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
    Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
    mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19.
    Mohseni Afshar Z; Tavakoli Pirzaman A; Karim B; Rahimipour Anaraki S; Hosseinzadeh R; Sanjari Pireivatlou E; Babazadeh A; Hosseinzadeh D; Miri SR; Sio TT; Sullman MJM; Barary M; Ebrahimpour S
    Diagnostics (Basel); 2023 Feb; 13(3):. PubMed ID: 36766664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
    Alam MS
    Heliyon; 2023 Feb; 9(2):e13285. PubMed ID: 36744070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Omicron Variant of the Sars-Cov-2 Virus As the Dominant Agent of a New Risk of Disease amid the COVID-19 Pandemic.
    Onishchenko GG; Sizikova TE; Lebedev VN; Borisevich SV
    Her Russ Acad Sci; 2022; 92(4):381-391. PubMed ID: 36091850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.